FOXO TECHNOLOGIES INC. Compensation Expense, Excluding Cost of Good and Service Sold
FOXO TECHNOLOGIES INC. (FOXO) reported Compensation Expense, Excluding Cost of Good and Service Sold of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold · last filed 2026-04-15
- FOXO TECHNOLOGIES INC. compensation expense, excluding cost of good and service sold for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- FOXO TECHNOLOGIES INC. compensation expense, excluding cost of good and service sold for fiscal 2024 was $8.84K, a 96.88% decline from fiscal 2023.
- FOXO TECHNOLOGIES INC. compensation expense, excluding cost of good and service sold for fiscal 2023 was $283.00K.
| Period end | Compensation Expense, Excluding Cost of Good and Service Sold 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-04-15 |
| 2024-12-31 | $8.84K 10-K · filed 2025-04-15 |
| 2023-12-31 | $283.00K 10-K · filed 2024-06-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |